Cardiac amyloidosis (CA) is caused by the accumulation of amyloid fibrils in the extracellular space of the myocardium, leading to clinical manifestations that include conduction disturbances and heart failure. CA was traditionally considered a rare disease with no effective therapies and a poor prognosis. In recent years, more options for non-invasive diagnosis and greater disease awareness have led to the identification of a growing number of cases, challenging the notion of CA as a rare disorder. The ability of recognizing and managing patients with CA should become part of the core curriculum of Cardiologists as well as Internal Medicine specialists, General Practitioners, Neurologists, Nephrologists and Hematologists. The Pisa Amyloid 2022 meeting will gather international experts of CA to the city of the leaning tower and will represent a unique opportunity to learn about CA for all audiences, as it will span from basic knowledge about CA to the forefront of scientific research.
Michele Emdin, Claudio Passino, Claudio Rapezzi, Giuseppe Vergaro